Increased activation of lymphocytes infiltrating primary colorectal cancers following immunisation with the anti-idiotypic monoclonal antibody 105AD7

Gut

Volumn 45, Issue 4, 1999, Pages 593-598

  Maxwell Armstrong, C A ^a   Durrant, L G ^a,b   Robins, R A ^c   Galvin, A M ^c   Scholefield, J H ^a   Hardcastle, J D ^a  

^a QUEEN S MEDICAL CENTRE   (United Kingdom)

^b NOTTINGHAM CITY HOSPITAL   (United Kingdom)

^c UNIVERSITY OF NOTTINGHAM   (United Kingdom)

Author keywords

105AD7; Anti idiotypic antibody; Colorectal cancer; Immunotherapy

Indexed keywords

ANTIIDIOTYPIC ANTIBODY; CD4 ANTIGEN; INTERLEUKIN 2 RECEPTOR; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN TISSUE; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE; LYMPHOCYTE ACTIVATION; MALE; PRIORITY JOURNAL;

EID: 0032831925     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.45.4.593     Document Type: Article

References (26)

1. OPCS. Mortality statistics by cause: England and Wales 1992. Series DH2, number 20. London HMSO, 1995.
2. Department of Health. On the state of the public health. The Annual Report of the Chief Medical Officer of the Department of Health. London: HMSO, 1991.
3. Maxwell-Armstrong CA, Durrant LG, Scholefield JH. Colorectal cancer vaccines. Br J Surg 1998;85:149-54.
4. Maxwell-Armstrong CA, Durrant LG, Scholefield JH. Immune treatment for colorectal cancer. In: Recent advances in surgery. London: Churchill Livingstone, 1998:97-111.
5. Austin EB, Robins RA, Durrant LG, et al. Human monoclonal anti-idiotypic antibody to the tumour-associated antibody 79IT/36. Immunology 1989;67:525-30.
6. Austin EB, Robins RA, Baldwin RW, et al. Induction of delayed hypersensitivity to human tumour cells with a human monoclonal anti-idiotypic antibody. J Natl Cancer Inst 1991;83:1245-8.
7. Denton GWL, Durrant LG, Hardcastle JD, et al. Clinical outcome of colorectal cancer patients treated with human monoclonal anti-idiotypic antibody. Int J Cancer 1995;57:10-14.
8. Robins RA, Denton GWL, Hardcastle JD, et al. Antitumor immune response and interleukin 2 production induced in colorectal cancer patients by immunisation with human monoclonal anti-idiotypic antibody. Cancer Res 1991;51:5425-9.
9. Jacob L, Somasundaram R, Smith W, et al. Cytotoxic T-cell clone against rectal carcinoma induced by stimulation of a patient's peripheral blood mononuclear cells with autologous cultured tumour cells. Int J Cancer 1997;71:325-32.
10. Durrant LG, Buckley TJD, Denton GWL, et al. Enhanced cell-mediated tumour killing in patients immunized with human monoclonal antiidiotypic antibody 105AD7. Cancer Res 1994;54:4837-40.
11. Buckley TJD, Robins RA, Durrant LC. Clinical evidence that the human monoclonal anti-idiotypic antibody 105AD7 delays tumor growth by stimulating anti-tumor T-cell responses. Hum Antibodies Hybridomas 1995;6:68-72.
12. Maxwell-Armstrong CA, Buckley TJD, Durrant LC, et al. The anti-idiotypic monoclonal antibody 105AD7 increases lymphocyte infiltration within colorectal tumours [abstract]. Br J Surg 1996;83:1650.
13. Waldmann TA, Coldwan CK, Robb RJ, et al. Expression of interleukin 2 receptors on activated human B cells. J Exp Med 1984;160:1450-66.
14. Wang HM, Smith KA. The interleukin-2 receptor: functional consequences of its bimolecular structure. J Exp Med 1987;166:1055-67.
15. Rees ADM, Scoging A, Dobson N, et al. T cell activation by antiidiotypic antibody: mechanism of interaction with antigen-reactive T cells. Eur J Immunol 1987;17:197.
16. Henney CS, Kuribayashi K, Kern DE, et al. Interleukin-2 augments natural killer cell activity. Nature 1981;291:333-8.
17. Trinchieri G, Matsumoto-Kobayashi M, Clark SC, et al. Response of resting human peripheral blood natural killer cells to interleukin. J Exp Med 1984;160:1147-69.
18. Smith T. The interleukin-2 receptor. Annu Rev Cell Biol 1989;5:397-425.
19. Harel-Bellan A, Bertoglio J, Quillet A, et al. Interleukin-2 up-regulates in own receptor on a subset or human unprimed peripheral blond lymphocytes and triggers their proliferation. J Immunol 1986;136:2463-9.
20. Berd D, Maguire HC Jr, Mastrangelo MJ, et al. Activation markers on T cells infiltrating melanoma metastases after therapy with dinitrophenyl-conjugated vaccine. Cancer Immunol Immunother 1994;39:141-7.
21. Weidmann E, Sacchi M, Plaisance S, et al. Receptors for interleukin-2 on human squamous cell carcinoma cell lines and tumor in situ. Cancer Res 1992;52:5963-70.
22. McMillan DN, Kernohan NB, Flett ME, et al. Interleukin-2 receptor expression and interleukin-2 localisation in human solid tumours in situ and in vitro: evidence for a direct role in the regulation of tumour cell proliferation. Int J Cancer 1995;60:766-72.
23. Hakansson L, Adell G, Boeryd B, et al. Infiltration of mononuclear inflammatory cells into primary colorectal carcinomas: an immunohistological analysis. Br J Cancer 1997;75:374-80.
24. Allen PM, Hogg N. Elevation of infiltrating mononuclear phagocytes in human colorectal tumors. J Natl Cancer Inst 1987;78:465.
25. Vose BM, Vanky F, Klein E. Human tumour-lymphocyte interaction in vitro. Comparison of the reactivity of tumour infiltrating blond and lymph-node lymphocytes with autologous tumour cells. Int J Cancer 1977;20:895-900.
26. Miescher S, Whiteside TL, Carrel S, et al. Functional properties of tumor-infiltrating and blood lymphocytes in patients with solid tumours: effects of tumor cells, and their supernatant on proliferative responses of lymphocytes. J Immunol 1986;136:1899-907.